PD-1 INHIBITOR
Clinical trials for PD-1 INHIBITOR explained in plain language.
Never miss a new study
Get alerted when new PD-1 INHIBITOR trials appear
Sign up with your email to follow new studies for PD-1 INHIBITOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple therapy targets tough brain metastases in lung cancer
Disease control Recruiting nowThis early-phase study is testing whether a combination of low-dose radiation to the whole brain, an immunotherapy drug (PD-1 inhibitor), and chemotherapy given directly into the spinal fluid can safely treat lung cancer that has spread to the lining of the brain and spinal cord.…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Radiation and immunotherapy join forces against tough pancreatic cancer
Disease control Recruiting nowThis early-phase study is testing whether adding low-dose radiation and an immunotherapy drug called pucotenlimab to standard chemotherapy can help control advanced pancreatic cancer. Ten adults with pancreatic cancer who haven't had prior immunotherapy will receive the combinati…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
New drug combo aims to save kidneys in pelvic cancer patients
Disease control Recruiting nowThis phase II trial tests whether a combination of tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy drug) can treat renal pelvic cancer while allowing patients to keep their kidney. About 35 adults with early-stage cancer will receive the drugs, and if the tumor…
Matched conditions: PD-1 INHIBITOR
Phase: PHASE2 • Sponsor: Tianjin Medical University Second Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC